2026-09-21 (filed)——
Recursion extends Tempus data deal at US$14M a year and licenses its TxFM model to Tempus for US$12M
A short entry: a summary of the public record, checked against its sources, not yet read and analysed by Gianluca. How the register works
On 15 September 2026 Recursion Pharmaceuticals and Tempus AI signed two agreements, reported in Recursion's 8-K dated 21 September. Recursion extended its data licence with Tempus, paying US$14 million a year for three years for access to fewer records, and licensed its TxFM RNA model to Tempus for oncology use for US$12 million plus pathology data.
What happened
- Data licence extended from five to six years; Recursion can no longer terminate it for convenience.
- Recursion pays Tempus US$14 million on each of the third, fourth and fifth anniversaries, at least US$4 million of each in cash, the rest in Recursion shares or cash.
- The number of unique de-identified records Recursion may access over the term goes down.
- Tempus gets a two-year, non-exclusive, worldwide licence to Recursion's TxFM RNA model, oncology only, for diagnostic, clinical and internal R&D use.
- Tempus pays US$12 million in two US$6 million instalments and gives Recursion access to de-identified pathology records with linked clinical data.
Who is involved
RecursionListed · NASDAQ: RXRX
Recursion is a clinical stage TechBio company decoding biology to radically improve lives.
Q2 2026 total revenue US$7.7M
Tempus AIListed · NASDAQ: TEM
Tempus does genome sequencing and precision medicine, including diagnostics, primarily for cancer patients.
Sources
- sec.gov — primary
- tempus.com — corroborating
- simplywall.st — party background
- sec.gov — party background
- fool.com — party background
Announced 2026-09-21 (filed)